Trials / Completed
CompletedNCT00994461
Study Of Celecoxib In Healthy Subjects
A Randomized, Placebo-Controlled, Double-Blind, Phase 4 Study To Compare The Effect Of Celecoxib 100 Mg BID, Loxoprofen 60 Mg TID And Placebo On The Gastroduodenal Mucosa In Healthy Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 40 Years – 74 Years
- Healthy volunteers
- Accepted
Summary
A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | Celecoxib 100mg tablet twice a day with meal for 2 weeks |
| DRUG | Loxoprofen | Loxoprofen 60mg tablet three times a day with meal for 2 weeks |
| DRUG | Placebo | Placebo tablet three times a day with meal for 2 weeks |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2009-10-14
- Last updated
- 2021-02-02
- Results posted
- 2011-05-17
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00994461. Inclusion in this directory is not an endorsement.